Mutant Prevention Concentration of Garenoxacin (BMS-284756) for Ciprofloxacin-Susceptible or -Resistant Staphylococcus aureus

The new quinolone garenoxacin (BMS-284756), which lacks a C-6 fluorine, was examined for its ability to block the growth of Staphylococcus aureus. Measurement of the MIC and the mutant prevention concentration (MPC) revealed that garenoxacin was 20-fold more potent than ciprofloxacin for a variety o...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Zhao, Xilin, Eisner, William, Perl-Rosenthal, Nathan, Kreiswirth, Barry, Drlica, Karl
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society for Microbiology 2003
Konular:
Mechanisms of Resistance
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC149307/
https://ncbi.nlm.nih.gov/pubmed/12604537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.47.3.1023-1027.2003
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller